By the Top Tier Newswire AI Desk · August 18, 2026 at 12:09 AM ET · reviewed against 3 wire stories
MESOBLAST LTD ADR (MESO) is up +9.14% in the latest session. Our newswire has captured 3 stories on MESO across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
MESO stock surged 9.14% to $17.02 on August 18, 2026, driven by the completion of patient treatment in its Phase 3 clinical trial for chronic low back pain. The trial, known as MSB-DR004, involves the allogeneic cell therapy rexlemestrocel-L and is a key milestone for the company. Investors are reacting positively to the progress, despite the fact that results are not expected until mid-2027.
What Happened
Mesoblast Limited announced that it has completed patient treatment in its Phase 3 MSB-DR004 trial of rexlemestrocel-L for chronic low back pain. This trial enrolled 350 patients and represents a pivotal step in the company's development pipeline. The completion of this phase is a major milestone for Mesoblast, which is a global leader in allogeneic cellular medicines for inflammatory diseases. The company has positioned this treatment to target a $10 billion market for regenerative back pain therapies. The news was reported by multiple sources, including InvestorsHub, The Fly, and Business Insider, all highlighting the significance of the trial's progress.
What The Data Shows
Despite the positive stock move, Mesoblast remains unprofitable, with a trailing twelve-month (TTM) earnings per share of -0.07 and a net margin of -144.3%. However, the company's revenue has grown significantly, rising 1,053.2% TTM. The stock has traded between $12.66 and $21.50 over the past 52 weeks. On August 18, it printed seven fresh 52-week lows, indicating a recent period of weakness before the rally. The stock's beta of 0.81 suggests it is less volatile than the broader market. The recent completion of the Phase 3 trial may signal a shift in investor sentiment.
What To Watch
The next key event for Mesoblast will be the release of Phase 3 trial results in mid-2027. Investors will be closely watching how the data is received by the market and whether it leads to regulatory submissions or partnerships. Coverage breadth is also a factor to monitor as the story continues to develop.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
MESO · Aug 18 session (5-min) · -2.23% vs prior close · updated 2:52 PM ETAI sentiment, last 36h · averaged over 3 stories · 63/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
26d agoInvestorsHubBULLISH 63Product/PR
Mesoblast shares jump as Phase 3 chronic back pain trial completes patient treatment
Mesoblast shares rise 9.5% after completing patient treatment in its Phase 3 rexlemestrocel-L trial for chronic low back pain, with results due in mid-2027.
27d agoThe FlyBULLISH 59Product/PR
Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial
27d agoBusiness InsiderBULLISH 67Product/PR
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →